Risk Summary
There are no adequate and well-controlled studies of ACUVUE® Theravison™ with Ketotifen administration in pregnant women to inform a drug-associated risk. ACUVUE® Theravison™ with Ketotifen is not absorbed systemically following ocular administration, and maternal use is not expected to result in fetal exposure to the drug. Oral administration of ketotifen fumarate to pregnant rats or rabbits did not produce teratogenicity at clinically relevant doses [see Data].
Data
Human Data
There are no human data that establish the presence or absence of drug-associated risk with the use of ACUVUE® Theravision™ with Ketotifen by pregnant women.
Animal Data
Oral administration of 45 mg/kg/day ketotifen to pregnant rabbits resulted in an increased incidence of retarded ossification of the sternebrae. This dose (normalized to body surface area) was approximately 23,000 times higher than the daily maximum recommended human ophthalmic dose (MRHOD) of 0.038 mg.
No adverse embryofetal effects were observed in rats or rabbits orally administered 100 mg/kg/day and 15 mg/kg/day, respectively, during organogenesis. These doses (normalized to body surface area) were approximately 26,000 and 7,700 times higher than the MRHOD, respectively.
An oral dose of 50 mg/kg/day ketotifen (approximately 13,000 times higher than MRHOD) administered to rats from Day 15 of pregnancy until Day 21 postpartum produced maternal toxicity, a slight increase in postnatal mortality and a slight decrease in body weight gain in offspring during the first four days post-partum.
Risk Summary
There is no information regarding the presence or absence of ketotifen fumarate or its metabolites in human milk following use of ACUVUE® Theravision™ with Ketotifen, or on the breastfed infants and milk production. Ketotifen fumarate has been identified in breast milk in rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in breast milk.
The development and health benefits of breastfeeding should be considered along with the mother's clinical need for ACUVUE® Theravision™ with Ketotifen and any potential adverse effects on the breast-fed child from ketotifen fumarate.
Physical/Optical Properties of the Lens:
| Refractive Index: | 1.40 |
| Visible Light Transmission: | 90% minimum |
| Ultraviolet Light Tranmission: (316 nm to 380 nm) UVA | 30% maximum |
| Ultraviolet Light Tranmission: (280 nm to 315 nm) UVB | 5% maximum |
| Surface Character: | Hydrophilic |
| Water Content: | 59% |
| Oxygen Permeability: | 21.4 × 10-11(cm2/sec) (mL O2/mL × mmHg) at 35°C (boundary corrected, edge corrected) |
Dimensional Properties of the Lens:
| Diameter: | 14.2 mm |
| Center Thickness: | Minus Lens - varies with power (e.g. -4.00D: 0.084 mm) |
| Plus Lens - varies with power (e.g. +4.00D: 0.190 mm) |
| Base Curve: | 8.5 mm and 9.0 mm |
| Power: | -0.50D to -10.00D (in 0.25D increments) |
| -10.50D to -12.00D (in 0.50D increments) |
| +0.50D to +6.00D (in 0.25D increments) |
Device Component
In its hydrated state, the lens when placed on the cornea, acts as a refracting medium to focus light rays on the retina to correct refractive ametropia for as long as the lens is worn (up to 24 hours while awake).
Drug Component
Ketotifen fumarate, a benzocycloheptathiophene derivative, is a H1 receptor antagonist that stabilizes mast cells and prevents eosinophil accumulation. This action prevents the onset of ocular allergic itch allowing for continued lens wear during episodes of allergen exposure and has been demonstrated to last through 12 hours.
Carcinogenesis
No information is available on the carcinogenic potential of ketotifen fumarate.
Mutagenesis
Ketotifen fumarate was determined to be non-mutagenic in a battery of in vitro and in vivo mutagenicity assays including: Ames test, in vitro chromosomal aberration test with V79 Chinese hamster cells, in vivo micronucleus assay in mouse, and mouse dominant lethal test. In addition, extracts of etafilcon A with ketotifen (19 mcg/lens) prepared in 0.9% sodium chloride or dimethyl sulfoxide were shown to be non-mutagenic in the Ames test.
Impairment of Fertility
Treatment of male rats with oral doses of ketotifen >10 mg/kg/day (approximately 2,600 times the MRHOD) for 70 days prior to mating resulted in mortality and a decrease in fertility. Treatment with ketotifen did not impair fertility in female rats receiving up to 50 mg/kg/day of ketotifen orally (approximately 13,000 times the MRHOD) for 15 days prior to mating.
Fitting
See the ACUVUE® Theravision™ with Ketotifen FITTING INSTRUCTION GUIDE for professional fitting instructions and information.
Wearing Schedule (Daily Wear)
Advise patients that ACUVUE® Theravision™ with Ketotifen should not be used to treat red eye(s). Remove lens(es) immediately if the eye(s) become red or irritated.
A single ACUVUE® Theravision™ with Ketotifen should be worn in each eye per day and should be discarded upon removal each day. The lens should not be worn beyond the period recommended by an eye care professional.
Advise patients that ACUVUE® Theravision™ with Ketotifen should be removed prior to sleep.
Lens Handling and Care
Advise patients to not use if the ACUVUE® Theravision™ with Ketotifen lens sterile blister package is opened or damaged.
Advise patients to always wash and rinse hands before handling lenses.
Advise patients to avoid contaminating hands or lenses with cosmetics, lotions, soaps, creams, deodorants or sprays. Instruct patients to put in lenses prior to applying makeup.
Advise patients not to touch contact lenses if hands have any foreign materials as microscopic scratches of the lenses may occur, which can cause distorted vision and/or injury to the eye.
Instruct patients to examine the lens after opening to be sure that it is a single, moist, clean lens that is free of any nicks or tears. If the lens appears damaged, patients should be instructed NOT to use it.
Instruct patients not to use contact lens cleaning and disinfectant solutions with ACUVUE® Theravision™ with Ketotifen. Discard lens after a single day's use.
Advise patients that ACUVUE® Theravision™ with Ketotifen should not be worn while swimming or in hot tubs. Contact lens wear in these settings increases the risk of sight threatening eye infections from microorganisms.
If the lens sticks (stops moving), the patient should be instructed to remove the lens. A few drops of non-preserved sterile saline solution may be applied directly to the eye to assist with removal. If non-movement of the lens continues after a few minutes, the patient should immediately consult their Eye Care Professional.
Patients should be advised to notify the employer of being a contact lens wearer. Some jobs may require the use of eye protection equipment or may require that the patient not wear contact lenses.
Advise patients to avoid all harmful or irritating vapors and fumes while wearing lenses. If aerosol products, such as hair spray, are used while wearing lenses, exercise caution and keep eyes closed until the spray has settled.
Instruct patients to never use tweezers, fingernails, or other tools to remove lenses from the lens container. Instead, patients should remove ACUVUE® Theravision™ with Ketotifen from the blister container packing solution using their fingertips. Patients should not touch the lens with fingernails.
The patients should be advised to never rinse the lenses in water from the tap. Tap water contains many impurities that can contaminate or damage the lenses and may lead to eye infection or injury.
Advise patients to always dispose of lenses when removed and have spare non-medicated lenses or spectacles available.
Concomitant Use of Other Medications
Advise patients to consult with their eyecare professional before using any medicine in the eyes. Advise patients that eye drops containing benzalkonium chloride should not be used simultaneously with ACUVUE® Theravision™ with Ketotifen. Instruct patients to wait 10 minutes after eye drop application before inserting lenses.
Daily self-examination
Instruct the patient to immediately remove the lens if any eye discomfort, eye pain, eye redness or decreased vision are experienced. If the symptoms stop after lens removal, the patient should discard the lens(es) and replace with new non-medicated lens(es). ACUVUE® Theravision™ with Ketotifen should not be worn for the remainder of the day. If the problem continue after inserting a new non-medicated lens, the patient should remove the lens and IMMEDIATELY CONSULT THEIR EYE CARE PROFESSIONAL.
Emergencies
Advise the patient that if chemicals of any kind (household products, gardening solutions, laboratory chemicals, etc.) are splashed into the eyes, the patient should: FLUSH EYES IMMEDIATELY WITH TAP WATER AND IMMEDIATELY CONTACT THE EYE CARE PROFESSIONAL OR VISIT A HOSPITAL EMERGENCY ROOM WITHOUT DELAY.
Symbols Key
The following symbols may appear on the label or packaging:
| SYMBOL | DEFINITION |
|---|
| Caution, Consult Instructions for Use |
| Manufacturer |
| Date of Manufacture |
| Use by Date (expiration date) |
| Batch Code |
| Sterilized Using Steam Heat |
| Do Not Re-Use (Single Use) |
| Do Not Use if Package is Damaged |
| Store Away from Direct Sunlight |
| Indicates a Single Sterile Barrier System |
| Authorized Representative in the European Community |
| Medical Device in the European Community |
| Fee Paid for Waste Management |
| CE-mark and Identification Number of Notified Body |
| Contains Hazardous Substances |
| Contains a Medicinal Substance |
| CAUTION: U.S. Federal law restricts this device to sale by or on the order of a licensed practitioner |
| CONTACT LENS | Contact Lens |
| Lens Orientation Correct |
| Lens Orientation Incorrect (Lens Inside Out) |
| Package Opening Icon (Blister) |
| DIA | Diameter |
| BC | Base Curve |
| D | Diopter (Lens Power) |
Distributed by:
Johnson & Johnson Vision Care, Inc.
7500 Centurion Parkway
Jacksonville, Florida 32256, USA
www.acuvue.com
©Johnson & Johnson Vision Care, Inc. 2021
In Canada: Johnson & Johnson Vision Care, division of Johnson & Johnson, Inc.
In USA: Johnson & Johnson Vision Care, Inc.
Printed in USA
Revision date: 2/2022
Revision number: XXXXX
ACUVUE® Theravision™ is a trademark of Johnson & Johnson Vision Care, Inc.